neomycin

Neomycin sulfate (Framycin sulfate) is a broad-spectrum aminoglycoside antibiotic that blocks the synthesis of bacterial proteins in order to exert antimicrobial activity. Neomycin sulfate is commonly used to screen prokaryotic and eukaryotic cells for Neo resistance genes.

Neomycin sulfate (Standard) is the standard substance of Neomycin sulfate, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Neomycin sulfate (Framycin sulfate) is a broad-spectrum aminoglycoside antibiotic that blocks the synthesis of bacterial proteins in order to exert antimicrobial activity. Neomycin sulfate is commonly used to screen prokaryotic and eukaryotic cells for Neo resistance genes.

Paromomycin II is an aminoglycoside antibiotic that exhibits activity against both Gram-positive and Gram-negative bacteria, mycobacteria, and protozoa. It is particularly effective in treating amoebic dysentery and certain bacterial dysentery cases.

6 '-Deamino-6 '-hydroxyneomycin B is an aminoglycoside antibiotic produced by [Streptomyces fradiaeUC 75]. It is effective against both Gram-positive and Gram-negative bacteria and serves as an intermediate in the biosynthesis of neomycin.

Vineomycin A1 (OS-4742 A1) is an antibiotic effective against Gram-positive bacteria, identified in *Streptomyces matensis* subsp. vineus. It has also demonstrated antitumor activity in mice and holds potential for research in skin fibrosis.

Paromomycin binds specifically to the RNA oligonucleotide at the A site of bacterial 30S ribosomes, thereby causing misreading and premature termination of translation of mRNA and inhibition of protein synthesis followed by cell death. Paromomycin Sulfate (Aminosidine sulfate) is the sulfate salt form of paromomycin, a structural derivative of neomycin, an aminoglycoside antibiotic with amebicidal and bactericidal effects against predominantly aerobic gram-negative bacteria.

Senfolomycin B exhibits activity against Gram-positive bacteria and mycobacteria, as well as effectiveness against penicillin-resistant, streptomycin-resistant, neomycin-resistant, and macrolide-antibiotic-resistant Staphylococcus aureus. Additionally, Senfolomycin A demonstrates weaker activity against Gram-negative bacteria.

Paulomycin B exhibits activity against gram-positive bacteria and inhibits Staphylococcus aureus that is resistant to penicillin, streptomycin, neomycin, and macrolide antibiotics.

Paulomycin A2 exhibits antibacterial activity against Gram-positive bacteria and specifically inhibits Staphylococcus aureus that is resistant to penicillin, streptomycin, neomycin, and macrolide antibiotics.

Paulomycin A (Volonomycin A) exhibits antibacterial activity against Gram-positive bacteria, effectively inhibiting penicillin-resistant, streptomycin-resistant, neomycin-resistant, and macrolide-resistant Staphylococcus aureus.

Senfolomycin A exhibits activity against Gram-positive bacteria and mycobacteria. It is also effective against penicillin-, streptomycin-, neomycin-, and macrolide-resistant Staphylococcus aureus. Additionally, Senfolomycin A has a weaker effect on Gram-negative bacteria.